



Advanced Research in Cancer Genomics and Genetics: Evolution from Single-Gene Analysis to AI-Driven Data Analysis of High-Throughput Data Generation

Guest Editor:

Dr. Roberto Piergentili
Consiglio Nazionale delle
Ricerche (CNR), Rome, Italy

Deadline for manuscript
submissions:

closed (30 April 2023)

Message from the Guest Editor

The advancement in omics disciplines, especially those directly involved in gene function and expression, as well as those describing the genome response to drugs in the treatment of various disorders allow us to have a comprehensive overview of gene activity inside cells in health and disease. The increasing power of technology in data retrieval allows us to collect huge amounts of information that need to be elaborated, to create models, and to set the basis for personalized medicine.

In this Special Issue, we welcome reviews, original research articles, and short communications that focus on, or are relevant to, the use of genetics and genomics approaches in cancer, the response of genes to environmental insults, and their up- or down-regulation upon drug administration, as well as new approaches for the early diagnosis and custom treatment of cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI